Posted in Business News Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting Editor September 21, 2020 Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam folder to confirm your subscription. Original Source
